Mark J. Bluth

3.0k citations

27 papers · 2.0k indexed · 2 hit papers · h-index 15

Impact in

Immunology top 2%
- Psoriasis: Treatment and Pathogenesis
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
Dermatology top 1%
- Dermatology and Skin Diseases

Papers in ⓘ

Oncology 16
- Cancer Immunotherapy and Biomarkers 9
- Cutaneous Melanoma Detection and Management 3
- CAR-T cell therapy research 3
Immunology 8
- Immunotherapy and Immune Responses 4
- Immune Cell Function and Interaction 3

Co-authors: James G. Krueger (6 shared papers)Mayte Suárez‐Fariñas (6 shared papers)Judilyn Fuentes‐Duculan (4 shared papers)Michelle A. Lowes (4 shared papers)Irma Cardinale (3 shared papers)Lisa C. Zaba (3 shared papers)Patricia Gilleaudeau (2 shared papers)Mary Sullivan‐Whalen (2 shared papers)
Journals: Journal of Clinical Oncology (8 papers)Journal of Investigative Dermatology (4 papers)The Journal of Experimental Medicine (2 papers)Cancer (1 paper)Clinical Cancer Research (1 paper)
Partner nations: United States Switzerland Saudi Arabia

In The Last Decade

Mark J. Bluth

26 papers receiving 1.9k citations

Hit Papers

align trajectories log scale

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers 2018 · 374 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Journal of Clinical Oncology
2007 The Journal of Experimental Medicine

Peers

Countries citing papers authored by Mark J. Bluth

Since Specialization

Citations

This map shows the geographic impact of Mark J. Bluth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Bluth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Bluth more than expected).

Fields of papers citing papers by Mark J. Bluth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Bluth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Bluth. The network helps show where Mark J. Bluth may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark J. Bluth, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark J. Bluth Line = papers co-authored together Mark J. Bluth links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses The Journal of Experimental Medicine ·Lisa C. Zaba, Irma Cardinale, Patricia Gilleaudeau, Mary Sullivan‐Whalen, Mayte Suárez‐Fariñas, Judilyn Fuentes‐Duculan, Inna Novitskaya, Artemis Khatcherian, Mark J. Bluth, Michelle A. Lowes, James G. Krueger Hit paper breakdown →	2007	540
2	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers Journal of Clinical Oncology ·Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya, Ashley Marie Regazzi, Brooke Kania, Meredith Moran, C Cipolla, Mark J. Bluth, Joshua Chaim, Hikmat Al‐Ahmadie, Alexandra Snyder, Maria I. Carlo, David B. Solit, Michael F. Berger, Samuel A. Funt, Jedd D. Wolchok, Gopa Iyer, Dean F. Bajorin, Margaret K. Callahan, Jacob Rosenberg Hit paper breakdown →	2018	374
3	Tumor-Associated Macrophages in the Cutaneous SCC Microenvironment Are Heterogeneously Activated Journal of Investigative Dermatology ·Julia S. Pettersen, Judilyn Fuentes‐Duculan, Mayte Suárez‐Fariñas, Katherine C. Pierson, Alexander Pitts-Kiefer, Linda Fan, Daniel A. Belkin, Claire Q. Wang, Shivaprasad Bhuvanendran, Leanne M. Johnson-Huang, Mark J. Bluth, James G. Krueger, Michelle A. Lowes, John A. Carucci	2011	163
4	Clinical activity of ipilimumab for metastatic uveal melanoma Cancer ·Jason J. Luke, Margaret K. Callahan, Michael A. Postow, Emanuela Romano, Nikhil H. Ramaiya, Mark J. Bluth, Anita Giobbie‐Hurder, Donald P. Lawrence, Nageatte Ibrahim, Patrick A. Ott, Keith T. Flaherty, Ryan J. Sullivan, James J. Harding, Sandra P. D’Angelo, Mark A. Dickson, Gary K. Schwartz, Paul B. Chapman, Jedd D. Wolchok, F. Stephen Hodi, Richard D. Carvajal	2013	143
5	Ipilimumab for Patients With Advanced Mucosal Melanoma The Oncologist ·Michael A. Postow, Jason J. Luke, Mark J. Bluth, Nikhil H. Ramaiya, Katherine S. Panageas, Donald P. Lawrence, Nageatte Ibrahim, Keith T. Flaherty, Ryan J. Sullivan, Patrick A. Ott, Margaret K. Callahan, James J. Harding, Sandra P. D’Angelo, Mark A. Dickson, Gary K. Schwartz, Paul B. Chapman, Sacha Gnjatic, Jedd D. Wolchok, F. Stephen Hodi, Richard D. Carvajal	2013	116
6	Conformation-dependent phosphorylation of p53 Proceedings of the National Academy of Sciences ·Victor Adler, Matthew R. Pincus, Toshinari Minamoto, Serge Y. Fuchs, Mark J. Bluth, Paul W. Brandt‐Rauf, Fred K. Friedman, Richard C. Robinson, James Chen, Xin Wei Wang, Curtis C. Harris, Ze’ev A. Ronai	1997	108
7	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab Clinical Cancer Research ·Sandra P. D’Angelo, Alexander N. Shoushtari, Mary Louise Keohan, Mark A. Dickson, Mrinal M. Gounder, Ping Chi, Jennifer K. Loo, Leigh Gaffney, Lee Schneider, Zarine Patel, Joseph P. Erinjeri, Mark J. Bluth, Ana Sjoberg, Howard Streicher, Naoko Takebe, Li‐Xuan Qin, Cristina R. Antonescu, Ronald P. DeMatteo, Richard D. Carvajal, William D. Tap	2016	98
8	The Human Cutaneous Squamous Cell Carcinoma Microenvironment Is Characterized by Increased Lymphatic Density and Enhanced Expression of Macrophage-Derived VEGF-C Journal of Investigative Dermatology ·Dariush Moussai, Hiroshi Mitsui, Julia S. Pettersen, Katherine C. Pierson, Kejal R. Shah, Mayte Suárez‐Fariñas, Irma Cardinale, Mark J. Bluth, James G. Krueger, John A. Carucci	2010	92
9	Myeloid Dendritic Cells from Human Cutaneous Squamous Cell Carcinoma Are Poor Stimulators of T-Cell Proliferation Journal of Investigative Dermatology ·Mark J. Bluth, Lisa C. Zaba, Dariush Moussai, Mayte Suárez‐Fariñas, Helen G. Kaporis, Linda Fan, Katherine C. Pierson, Traci R. White, Alexander Pitts-Kiefer, Judilyn Fuentes‐Duculan, Emma Guttman‐Yassky, James G. Krueger, Michelle A. Lowes, John A. Carucci	2009	77
10	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies Cancer Discovery ·Omar Abdel‐Wahab, Virginia M. Klimek, Alisa A. Gaskell, Agnès Viale, Donavan T. Cheng, Eun Hee Kim, Raajit K. Rampal, Mark J. Bluth, James J. Harding, Margaret K. Callahan, Taha Merghoub, Michael F. Berger, David B. Solit, Neal Rosen, Ross L. Levine, Paul B. Chapman	2014	59
11	Langerhans Cells from Human Cutaneous Squamous Cell Carcinoma Induce Strong Type 1 Immunity Journal of Investigative Dermatology ·Hideki Fujita, Mayte Suárez‐Fariñas, Hiroshi Mitsui, Juana Gonzalez, Mark J. Bluth, Shali Zhang, Diane Felsen, James G. Krueger, John A. Carucci	2012	36
12	Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma Melanoma Research ·Alexander N. Shoushtari, Mark J. Bluth, Debra A. Goldman, Christiana Bitas, Robert A. Lefkowitz, Michael A. Postow, Rodrigo Ramella Munhoz, Gauri Buchar, Robert Harrison Hester, Jacqueline Romero, Laura Fitzpatrick, Martin R. Weiser, Katherine S. Panageas, Jedd D. Wolchok, Paul B. Chapman, Richard D. Carvajal	2016	33
13	Stroke following Chiropractic Manipulation Cerebrovascular Diseases ·Joseph S. Jeret, Mark J. Bluth	2002	27
14	Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses The Journal of Experimental Medicine ·Lisa C. Zaba, Irma Cardinale, Patricia Gilleaudeau, Mary Sullivan‐Whalen, Mayte Suárez‐Fariñas, Judilyn Fuentes‐Duculan, Inna Novitskaya, Artemis Khatcherian, Mark J. Bluth, Michelle A. Lowes, James G. Krueger	2008	16
15	Ipilimumab in the treatment of uveal melanoma: The Memorial Sloan-Kettering Cancer Center experience. Journal of Clinical Oncology ·Shaheer Khan, Margaret K. Callahan, Michael A. Postow, Paul B. Chapman, Gary K. Schwartz, Mark A. Dickson, Sandra P. D’Angelo, Jason J. Luke, Mark J. Bluth, Ruth Román, Mary Montefusco, Christopher A. Barker, David H. Abramson, Jedd D. Wolchok, Richard D. Carvajal	2012	15
16	DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC). Journal of Clinical Oncology ·Min Yuen Teo, Kenneth Seier, Irina Ostrovnaya, Ashley Marie Regazzi, Brooke Kania, Meredith Moran, C Cipolla, Mark J. Bluth, Joshua Chaim, Hikmat Al‐Ahmadie, David B. Solit, Samuel A. Funt, Jedd D. Wolchok, Gopa Iyer, Alexandra Snyder, Dean F. Bajorin, Jonathan E. Rosenberg, Margaret K. Callahan	2017	12
17	Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas. Journal of Clinical Oncology ·Alexander N. Shoushtari, Sandra P. D’Angelo, Mary Louise Keohan, Mark A. Dickson, Mrinal M. Gounder, Abdul Karim Abdullah, Joseph P. Erinjeri, Mark J. Bluth, Yelena Ustoyev, Mercedes M. Condy, Howard Streicher, Naoko Takebe, Ronald P. DeMatteo, Gary K. Schwartz, William D. Tap, Richard D. Carvajal	2014	11
18	Peripheral Blood Mononuclear Cell Gene Array Profiles in Patients With Overactive Bladder Urology ·Wellman Cheung, Mark J. Bluth, (unknown), Christopher Johns, Sohail Khan, Yin Lin, Martin H. Bluth	2009	10
19	Molecular Pathology Techniques Clinics in Laboratory Medicine ·Mark J. Bluth, Martin H. Bluth, (unknown), (unknown)	2018	9
20	Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC). Journal of Clinical Oncology ·Margaret K. Callahan, Brooke Kania, Gopa Iyer, Jessica Clément, Samuel A. Funt, Asia S. McCoy, Grace Hettich, Etay Ziv, Mark J. Bluth, Phillip Wong, Jedd D. Wolchok, Dean F. Bajorin, Jonathan E. Rosenberg	2017	7

About Mark J. Bluth

Mark J. Bluth is a scholar working on Oncology, Immunology, Gastroenterology, Ophthalmology and Urology, having authored 27 papers that have together received 2.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Bladder and Urothelial Cancer Treatments (6 papers), Immunotherapy and Immune Responses (4 papers), Cutaneous Melanoma Detection and Management (3 papers), Melanoma and MAPK Pathways (3 papers), CAR-T cell therapy research (3 papers), Epigenetics and DNA Methylation (3 papers) and Immune Cell Function and Interaction (3 papers). The work is most often cited by research in Immunology (1.0k citations), Dermatology (338 citations), Oncology (960 citations), Ophthalmology (125 citations) and Gastroenterology (54 citations). Mark J. Bluth has collaborated with scholars based in United States, Switzerland and Saudi Arabia. Frequent co-authors include James G. Krueger, Mayte Suárez‐Fariñas, Judilyn Fuentes‐Duculan, Michelle A. Lowes, Irma Cardinale, Lisa C. Zaba, Patricia Gilleaudeau, Mary Sullivan‐Whalen, Artemis Khatcherian and Inna Novitskaya. Their work appears in journals such as Journal of Clinical Oncology, Journal of Investigative Dermatology, The Journal of Experimental Medicine, Cancer and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact